metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Potential clinical significance of statins on methicillin resistance reversion i...
Información de la revista
Vol. 40. Núm. 4.
Páginas 214-215 (abril 2022)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
287
Vol. 40. Núm. 4.
Páginas 214-215 (abril 2022)
Scientific letter
Acceso a texto completo
Potential clinical significance of statins on methicillin resistance reversion in Staphylococcus aureus
Potencial significado clínico de las estatinas en la reversión de la resistencia a meticilina en Staphylococcus aureus
Visitas
287
Jesús Machucaa,
Autor para correspondencia
, María Carmen Conejob, Álvaro Pascuala,b,c,d, José Manuel Rodríguez-Martínezb,c,d
a Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena, Seville, Spain
b Departamento de Microbiología, Facultad de Medicina, Universidad de Sevilla, Seville, Spain
c Red Española de Investigación en Patología Infecciosa (REIPI), Instituto de Salud Carlos III, Madrid, Spain
d Instituto de Biomedicina de Sevilla IBIS, Hospital Universitario Virgen Macarena/CSIC/Departamento de Microbiología, Universidad de Sevilla, Seville, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. Oxacillin MIC of MRSA clinical isolates in the presence of the lactone form of simvastatin.
Texto completo
Dear Editor,

Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of hospital-acquired and healthcare-associated infections worldwide.1 MRSA bacteremia is associated with higher mortality than methicillin-susceptible S. aureus bacteremia.2 For MRSA bacteremia, the IDSA guidelines recommend treatment with vancomycin or daptomycin.3 However, strains showing higher vancomycin MICs have been associated with increased risk of treatment failure and death,4 and the emergence of non-susceptible mutants with daptomycin treatment is concerning.5 In view of these therapeutic difficulties, one possibility is to search for adjuvant substances that allow the continued use of conventional antimicrobials. Some studies have found that statins treatment has a protective effect against both mortality and the development of persistent bacteremia in patients with S. aureus bacteremia.6,7 Statins have no intrinsic bactericidal activity against S. aureus,8 but synergize with different antimicrobials to increase their bactericidal effect.9 In addition, it has been shown that several statins can reverse methicillin resistance in the community-associated MRSA strain USA300.8 Despite this phenomenon was confirmed in an experimental murine model,8 significant questions remain unresolved, and no studies have evaluated the impact of statins as a strategy to reverse methicillin resistance against clinical isolates of MRSA under human therapeutic concentrations. We tested statins against a set of clinical isolates of MRSA belonging to the most prevalent high-risk clones in human infections to address this question.

Nineteen MRSA isolates recovered from patients with nosocomial or healthcare-associated bacteremia were selected for this study. Isolates belonged to the following high-risk clones: ST5 (thirteen isolates), ST8 (four isolates), ST22 (one isolate) and ST45 (one isolate). Thirteen isolates belonged to agr group II and the remainder to agr group I. All isolates harboured SCCmec type IV, and none of the isolates carried Panton-Valentine leukocidin genes.10S. aureus ATCC 29213 and MRSA USA300 strains were included as controls.

The active forms of five statins were tested: fluvastatin, rosuvastatin, atorvastatin, simvastatin and lovastatin (Axxora, Brussels, Belgium). In the case of simvastatin and lovastatin, the prodrug form (lactone) was also included (Axxora). Susceptibility to statins and oxacillin (Sigma-Aldrich, Madrid, Spain) was determined by broth microdilution. All isolates showed MIC values of all statins tested above 200μmol/L and oxacillin MICs16mg/L (Table 1). Statin–oxacillin synergy was evaluated using the chequerboard method. None of the statins evaluated showed synergistic effects with oxacillin, except for the prodrug form of simvastatin. The lactone form of simvastatin reversed methicillin resistance (defined as the reduction of oxacillin MIC to ≤2mg/L) in eighteen isolates (95%) at 400μmol/L, and in seventeen isolates (89%) at 200μmol/L. However, methicillin resistance reversion was not observed in any isolate at lower concentrations of simvastatin (Table 1). The MIC of the lactone form of simvastatin was >800μmol/L, which means that this effect is observed at sub-MIC concentrations of simvastatin.

Table 1.

Oxacillin MIC of MRSA clinical isolates in the presence of the lactone form of simvastatin.

Strain  Sequence type  SSCmec type  Agr group  Oxacillin MIC (mg/L)a
        400μmol/L SIMb  200μmol/L SIM  100μmol/L SIM  50μmol/L SIM  25μmol/L SIM  12.5μmol/L SIM  6.25μmol/L SIM  0μmol/L SIM 
ATCC 29213  –  –  –  0.125  0.125  0.125  0.125  0.125  0.125  0.125  0.125 
MRSA USA300  ST8  SSCmec IV  agr0.06  0.06  16  16  16  16  16 
MRSA 14  ST5  SSCmec IV  agrII  64  64  64  64  64 
MRSA 15  ST5  SSCmec IV  agrII  64  64  64  64  64  64 
MRSA 16  ST5  SSCmec IV  agrII  32  32  32  32 
MRSA 17  ST5  SSCmec IV  agrII  0.06  0.06  16  64  64  64  64  64 
MRSA 18  ST5  SSCmec IV  agrII  0.06  0.06  32  32  32  32  32  32 
MRSA 19  ST5  SSCmec IV  agrII  0.06  0.06  16  16  16  16  16 
MRSA 20  ST5  SSCmec IV  agrII  0.06  0.06  64  64  64  64  64 
MRSA 21  ST5  SSCmec IV  agrII  0.06  0.06  64  64  64  64  64 
MRSA 22  ST5  SSCmec IV  agrII  0.06  0.06  32  32  32  32  32 
MRSA 23  ST5  SSCmec IV  agrII  0.06  0.06  32  32  32  32  32  32 
MRSA 24  ST5  SSCmec IV  agrII  0.06  0.06  16  16  16  16  16  16 
MRSA 25  ST5  SSCmec IV  agrII  0.06  0.06  32  64  64  64  64  64 
MRSA 26  ST5  SSCmec IV  agrII  0.06  0.06  16  64  64  64  64  64 
MRSA 27  ST8  SSCmec IV  agr0.06  0.06  32  32  32  32  32 
MRSA 28  ST8  SSCmec IV  agr0.06  0.06  32  32  32  32  32  32 
MRSA 29  ST8  SSCmec IV  agr0.06  0.06  16  32  32  32  32  32 
MRSA 30  ST8  SSCmec IV  agr0.06  0.06  0,06  64  64  64  64  64 
MRSA 32  ST22  SSCmec IV  agr0.06  0.06  16  128  128  128  128  128 
MRSA 33  ST45  SSCmec IV  agr0.06  0.06  16  32  32  32  32 
a

According to EUCAST breakpoints, S. aureus isolates with oxacillin MIC values >2mg/L are mostly methicillin-resistant due to the presence of the mecA or mecC genes.

b

SIM: lactone form of simvastatin (inactive form).

Several studies have shown the pleiotropic effects of statins, including bactericidal activity against gram-positive bacteria, such as S. pneumoniae, and reversion of methicillin resistance in S. aureus.8,11 These effects were detected at statin concentrations of 1–100μmol/L. Nevertheless, the mean concentration of statins in human serum is only 1–15nmol/L, and the peak concentration is 6–50nmol/L, with this concentration being reached in serum for a very short period of time.12

According to our results, the inactive form of simvastatin is the only statin tested which is able to reverse methicillin resistance in S. aureus clinical isolates, although this effect was observed at sub-MIC simvastatin concentrations above 100μmol/L. Moreover, this concentration of statin is much higher than that reached in serum with therapeutic doses, so that it cannot be used as a potential adjuvant to reverse methicillin resistance. Why this effect is not observed with the prodrug form of simvastatin remains unknown.

These results contrast with those previously found in a murine model of pulmonary infection.8 This discrepancy might be partially explained by the differences in dosage. In humans, the dosage of statins is approximately 0.1–1mg/kg, while in the murine model, doses of 20 and 50mg/kg were used. However, these doses were similar to those used in previous in vitro studies.11 The metabolism, pharmacodynamics and action of statins differ in humans and mice so that the results observed in murine models should be taken with caution before being applied to humans.

This study shows that simvastatin maybe a potential strategy to reverse methicillin resistance in S. aureus, although, unfortunately, this effect is not observed at therapeutic human concentrations.

Funding

This work was supported by the Plan Nacional de I+D+i 2017–2020 and the Instituto de Salud Carlos III (project PI18/00715), Subdirección General de Redes y Centros de InvestigaciónCooperativa, Ministerio de Economía, Industria y Competitividad, the Spanish Network for Research in Infectious Diseases (REIPI; RD16/0016/0001 and REIPI RD16/0016/0009), co-financed by the European Development Regional Fund“A Way to Achieve Europe,” operative programme Intelligent Growth 2014–2020.

Conflicts of interest

None to declare.

Acknowledgement

The authors would like to thank Dr. Carmen Velasco for giving us the S. aureus clinical isolates used in this study.

References
[1]
B. Limbago, G.E. Fosheim, V. Schoonover, C.E. Crane, J. Nadle, S. Petit, et al.
Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis.
J Clin Microbiol, 47 (2009), pp. 1344-1351
[2]
S.E. Cosgrove, G. Sakoulas, E.N. Perencevich, M.J. Schwaber, A.W. Karchmer, Y. Carmeli.
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.
Clin Infect Dis, 36 (2003), pp. 53-59
[3]
C. Liu, A. Bayer, S.E. Cosgrove, R.S. Daum, S.K. Fridkin, R.J. Gorwitz, et al.
Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
Clin Infect Dis, 52 (2011), pp. e18-e55
[4]
A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, V.P. Dimova, et al.
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis, 46 (2008), pp. 193-200
[5]
M. Sharma, K. Riederer, P. Chase, R. Khatib.
High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia.
Eur J Clin Microbiol Infect Dis, 27 (2008), pp. 433-437
[6]
L.E. López-Cortés, J. Gálvez-Acebal, M.D. Del Toro, C. Velasco, M. de Cueto, F.J. Caballero, et al.
Effect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: a prospective cohort study.
[7]
J. Smit, L.E. López-Cortés, R.W. Thomsen, H.C. Schønheyder, H. Nielsen, T. Frøslev, et al.
Statin use and risk of community-acquired Staphylococcus aureus bacteremia: a population-based case–control study.
Mayo Clin Proc, 92 (2017), pp. 1469-1478
[8]
E. García-Fernández, G. Koch, R.M. Wagner, A. Fekete, S.T. Stengel, J. Schneider, et al.
Membrane microdomain disassembly inhibits MRSA antibiotic resistance.
Cell, 171 (2017), pp. 1354-1367
[9]
L.-A. Pauchard, M. Blot, R. Bruyere, S.-D. Barbar, D. Croisier, L. Piroth, et al.
Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilation.
PLoS One, 12 (2017), pp. e0187187
[10]
C. Velasco, L.E. López-Cortés, F.J. Caballero, J.A. Lepe, M. de Cueto, J. Molina, et al.
Clinical and molecular epidemiology of meticillin-resistant Staphylococcus aureus causing bacteraemia in Southern Spain.
J Hosp Infect, 81 (2012), pp. 257-263
[11]
P. Bergman, C. Linde, K. Pütsep, A. Pohanka, S. Normark, B. Henriques-Normark, et al.
Studies on the antibacterial effects of statins – in vitro and in vivo.
[12]
J.E. Keskitalo, M.K. Pasanen, P.J. Neuvonen, M. Niemi.
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Pharmacogenomics, 10 (2009), pp. 1617-1624
Copyright © 2021. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos